A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Latest Information Update: 25 Sep 2024
At a glance
- Drugs Spartalizumab (Primary) ; WNT 974 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Cervical cancer; Colorectal cancer; Head and neck cancer; Lung cancer; Male breast cancer; Malignant melanoma; Oesophageal cancer; Pancreatic cancer; Squamous cell cancer; Triple negative breast cancer; Uveal melanoma
- Focus Adverse reactions
- Sponsors Novare Pharmaceuticals; Novartis; Novartis Pharmaceuticals
Most Recent Events
- 06 Sep 2024 Status changed from active, no longer recruiting to completed.
- 14 Mar 2024 Planned End Date changed from 28 Jun 2024 to 18 Jun 2024.
- 27 Apr 2023 Planned End Date changed from 23 Nov 2023 to 28 Jun 2024.